biostudies-literatureUnknown10(1)Takeuchi S<h4>Background</h4>Rearranged during transfection (<i>RET</i>) rearrangements occur in 1-2% of non-small cell lung cancers (NSCLCs). Alectinib administered at doses of 300 mg and 600 mg twice daily (BID) is approved for.<h4>Alk</h4>rearranged NSCLC in Japan and other countries, respectively. Since alectinib has activity against RET, we conducted a phase (P) 1/2 study of alectinib to determine its activity in Japanese patients with.<h4>Ret</h4>rearranged NSCLC.<h4>Methods</h4>This study was a single-arm, open-label, multi-institutional P1/2 trial. Previously treated patients with <i>RET</i>-rearranged NSCLC, screened by nation-wide network (LC-SCRUM-Japan), were recruited. In P1, alectinib (600 or 450 mg BID) was administered following a 3+3 design and its safety was assessed. During P2, alTranslational lung cancer research314-325https://www.ebi.ac.uk/biostudies/studies/S-EPMC7867784biostudies-literaturePhase 1/2 study of alectinib in RET-rearranged previously-treated non-small cell lung cancer (ALL-RET).PMC7867784Matsumoto SHattori YMurayama TSeto TYoshimura KOhashi KYoh KTakeuchi SMorise MNishiyama ATanimoto ANishio MGoto KYano SYanagitani NImai YTakahara SKawakami TfalsePhase 1/2 study of alectinib in RET-rearranged previously-treated non-small cell lung cancer (ALL-RET).<h4>Background</h4>Rearranged during transfection (<i>RET</i>) rearrangements occur in 1-2% of non-small cell lung cancers (NSCLCs). Alectinib administered at doses of 300 mg and 600 mg twice daily (BID) is approved for.<h4>Alk</h4>rearranged NSCLC in Japan and other countries, respectively. Since alectinib has activity against RET, we conducted a phase (P) 1/2 study of alectinib to determine its activity in Japanese patients with.<h4>Ret</h4>rearranged NSCLC.<h4>Methods</h4>This study was a single-arm, open-label, multi-institutional P1/2 trial. Previously treated patients with <i>RET</i>-rearranged NSCLC, screened by nation-wide network (LC-SCRUM-Japan), were recruited. In P1, alectinib (600 or 450 mg BID) was administered following a 3+3 design and its safety was assessed. During P2, al2021-01-01T00:00:00Z2021 Jan2025-04-26T18:25:59.692Z2025-02-19T01:40:39.668ZS-EPMC78677843356931510.21037/tlcr-20-549